Fresh analysis indicates that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.
Research printed in a major medical journal points out that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Users purchasing such medications should be aware of the risk of fast rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to starting weight in about 18 months.
Analyzing Treatments
The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with conventional dieting.
Researchers note that people who shed pounds through diet and exercise typically see a more gradual weight regain—around 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Experts propose the way of the injections accounts for the amplified rebound.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than normal may cause the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the likelihood of weight regain, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the long-term nature of excess weight," akin to managing conditions like high blood pressure.
User Accounts
Users who have stopped the jabs describe a intense return of cravings.
"It was like something flipping and I was suddenly ravenous," said one woman.
This difficulty is compounded if individuals have not established lasting dietary or behavioural changes during treatment.
Widespread Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle changes.
